Shenzhen Salubris Pharmaceuticals' (SHE:002294) three drugs were included in China's National Basic Medical Insurance, Maternity Insurance and Work Injury Insurance Drug Catalog, according to a Shenzhen bourse filing on Tuesday.
Xinchaotuo or sacubitril and alisartan calcium tablets and Fulian or alisartan ester and indapamide sustained-release tablets were newly included in the list, while Enaro or ennadustat tablets were renewed and retained.
Meanwhile, Xilitan or alisartan tablets were adjusted to routine management under the catalog.
The catalog will be valid between Jan. 1, 2026, and Dec. 31, 2027.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments